PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 1, 2026Anticancer Research0 citations

Immunohistochemical Expression and Clinicopathological Assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 Expression in Desmoid Tumor

KHKAZUHIKO HASHIMOTOSNSHUNJI NISHIMURAHTHiroki Tan

Key Points

  • This research aims to investigate the expression patterns of immune checkpoint pathways and associated molecular markers in desmoid tumors.
  • Conducted immunohistochemical analysis on biopsy specimens from patients with desmoid tumors.
  • Analyzed expression frequencies of PD-1, PD-L1, NY-ESO-1, MAGE-A4, CD4, and CD8 markers.
  • Correlated immune marker expressions with patient demographics and tumor characteristics.
  • Percentage of cells positive for PD-1 and PD-L1 was notably low, indicating limited immune checkpoint activity.
  • NY-ESO-1 and MAGE-A4 exhibited higher expression levels compared to PD-1 and PD-L1.
  • Moderate positive correlations were found between β-catenin and CD4, NY-ESO-1, while CD4 correlated moderately with PD-L1.

Abstract

Background/Aim: The action of immune molecular mechanisms in the intratumor microenvironment in desmoid tumors (DTs) remains unclear. The purpose of this research was to clarify the expression patterns of PD-1/PD-L1 immune checkpoint pathways and NY-ESO-1/MAGE-A4 molecular pathways in DTs. Materials and Methods: Immunohistochemical analysis of CD4, CD8, PD-1, PD-L1, NY-ESO-1, and MAGE-A4 were carried out on biopsy specimens collected from patients with DT managed at our hospital. In addition, relationships between the expression frequencies of each immune marker were explored. Results: In this study, four male and five female patients were recruited, with a mean age of 37.0 years (range=11-84 years). The average ± S.D. percentage of cells positive for β-catenin, CD4, CD8, PD-1, PD-L1, NY-ESO-1, and MAGE-A4 was 43.9±18.9, 14.6±6.80, 0.75±4.70, 0±0, 5.1±6.73, 30±21.6, and 68.9±20.8, respectively. β-catenin correlated moderately and positively with CD4 (r=0.49), weakly and positively with PD-L1 (r=0.25), and strongly and positively with NY-ESO-1 (r=0.52). CD4 showed a moderate positive correlation with PD-L1 (r=0.36), while NY-ESO-1 correlated moderately and positively with MAGE-A4 (r=0.42). Conclusion: The NY-ESO-1/MAGEA4 immune pathway may play a more prominent role than the PD-1/PD-L1 checkpoint pathway within the tumor microenvironment of DT.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

HASHIMOTO et al. (2026) studied this question.

synapsesocial.com/papers/69a3d8e7ec16d51705d30386https://doi.org/10.21873/anticanres.18037
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma2024 · 15 citations
  2. 2Abstract 6472: Tumor-cell NY-ESO-1 expression predicts poor response to PD-1/PD-L1 blockade in NSCLC2026
  3. 3Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors2026
  4. 4Abstract 2513: MAGE-A3, MAGE-A4, and PD-L1 protein show co-expression in colon, lung and bladder cancer2024
  5. 5Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome2024